Imagene AI Secures $23M Series B Funding to Revolutionize AI-Driven Precision Oncology

Imagene AI is thrilled to announce a major funding milestone with a successful raise of $23,000,000, propelling our mission to revolutionize cancer research and diagnostics. As a pioneering company in AI-based precision oncology, Imagene is dedicated to decoding cancer using biopsy images—a breakthrough approach designed to unveil the complexities of oncology with greater precision than ever before. This latest investment will accelerate our development and expansion of cutting-edge technologies that lie at the heart of our operations, including Imagene’s flagship OISuite. Powered by our state-of-the-art pathology foundation model, OISuite is a versatile platform enabling the development of diverse applications that streamline disease profiling and accelerate discoveries in oncology. A standout innovation from Imagene is LungOI, our AI-driven NSCLC multi-gene test, which leverages the power of our foundation model to offer rapid biomarker profiling that informs critical clinical decisions. This functional integration of AI in health diagnostics is already turning heads in the industry, having earned us the Digital Health Award for “Best Use of AI in HealthTech” as well as the Technology Leadership Best Practices Award from Frost & Sullivan. The funding will not only bolster further advancement of these revolutionary tools but will also fuel research and development initiatives aimed at expanding the capabilities of Oncology Intelligence. Our commitment to enhancing patient care and empowering clinicians with actionable insights remains unwavering as we continue to push the boundaries of what is possible in precision oncology. With the support of our investors and the broader medical community, Imagene AI is poised to lead the next chapter in transforming cancer diagnostics and therapy worldwide.